Skip to main content

Angiodynamics Value Stock - Dividend - Research Selection

Angiodynamics

ISIN: US03475V1017 , WKN: A0B9A5

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Nutriband Inc. (NTRB) Reports Q2 Loss, Lags Revenue Estimates

2025-09-09
Nutriband (NTRB) delivered earnings and revenue surprises of -1,147.06% and -11.77%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

With AngioDynamics Up 11%, Insider Buyers Count Their Returns

2025-08-27
AngioDynamics, Inc. ( NASDAQ:ANGO ) insiders who bought shares over the past year were rewarded handsomely last week...

Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

2025-08-21
ANGO benefits from NanoKnife, clinical milestones, and a balanced portfolio despite tariff headwinds.

AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul

2025-08-17
AngioDynamics has transformed into a focused MedTech player with rising sales, positive EBITDA, and strong growth drivers. Learn why ANGO stock is a buy.

Europe Neonatal Intensive Care Market Growth and Company Analysis Report 2025-2033 Featuring Masimo, 3M, Medtronic, Koninklijke Philips, Siemens, Terumo, AngioDynamics, Dragerwerk

2025-08-14
The Europe Neonatal Intensive Care Market is poised to grow from US$ 1.04 billion in 2024 to US$ 1.60 billion by 2033, boasting a CAGR of 4.96%. This growth is propelled by rising preterm birth rates, neonatal technology advancements, government regulations, and expanding hospital infrastructure, particularly in Eastern Europe. Key sectors include incubators, ventilators, and monitoring devices. Countries like Germany, France, and the UK are leading due to their robust NICU facilities and height

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

2025-08-06
LATHAM, N.Y., August 06, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference at 9:00

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

2025-07-28
LATHAM, N.Y., July 28, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first patient in the Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Li

Venous Thromboembolism Treatment Devices Market Insights, Competitive Landscape, and Forecast Report 2032 Featuring Abbott, Boston Scientific, AngioDynamics, Argon Medical Devices, and Medtronic

2025-07-25
The Venous Thromboembolism Treatment Devices Market is poised for significant growth, projected to expand at a CAGR of 8.31% from 2025 to 2032. Factors such as rising deep vein thrombosis and pulmonary embolism rates, fueled by aging populations, sedentary lifestyles, and chronic diseases, drive demand. Key market players are innovating with advanced devices, enhancing treatment effectiveness. North America leads the market owing to technological advancements and high disease prevalence. Notable

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

2025-07-23
LATHAM, N.Y., July 23, 2025--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of results from the PRESERVE study, which assessed the safety and effectiveness of irreversible electroporation (IRE) with the NanoKnife System to ablate prostate tissue in patients with intermediate-ri

Tumor Ablation Market Research Report 2025-2032 | Radiofrequency Ablation Leads, Offering Efficiency and Specificity Across Key Organ Treatments

2025-07-18
The global tumor ablation market is projected to surge from USD 1.67 billion in 2024 to USD 4.15 billion by 2032. Driven by advancements in minimally invasive techniques like radiofrequency and microwave, the market benefits from precision treatments aligned with the rise of personalized medicine. Key players include AngioDynamics and Stryker.Dublin, July 18, 2025 (GLOBE NEWSWIRE) -- The "Tumor Ablation Market (By Technology, Treatment Mode, Application, End-User, Regional Analysis), Company Pro